| Catalog No. |
TD-VK565026 |
| Species reactivity |
SARS-CoV-2 (2019-nCoV) |
| Applications |
Research Grade Biosimilar |
| Host species |
Human |
| Isotype |
IgG1, kappa |
| Expression system |
Mammalian Cells |
| Clonality |
Monoclonal |
| Target |
Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2, Spike protein S2', S, 2 |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G, purified from cell culture supernatant. |
| Accession |
P0DTC2 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS,pH7.4. |
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Background |
Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection. |
| Note |
For research use only. Not for use in clinical or therapeutic applications. |